Collagen Solutions develops, manufactures and supplies medical grade collagen components for use in regenerative medicine, medical devices and research. Our services offer product development and contracting manufacturing, which includes technology transfer and regulatory support. Collagen Solutions is publicly traded on the London Stock exchange (COS) and headquartered in Glasgow, Scotland with sites in the United States and New Zealand.
• Production of bovine collagen type I for clinical trial MPC delivery. COS will provide medical grade GMP bovine collagen for manufacturing of the final cell delivery product for use in clinical trials. Product quality will be verified.
• Development of xeno-free collagen. COS will develop and optimize a system for the manufacture of human collagen type I from human fibroblasts using either spin or hollow fiber cell culture. In spin culture, fibroblasts will be seeded on microcarriers within a media suspension. In hollow fiber culture, fibroblasts will be seeded on bundles of hollow, porous tubes through which media will circulate and provide cells with necessary nutrients. In both systems, the fibroblasts will produce xeno-free collagen, which will be harvested. The most efficient system will be scaled-up to a full GMP process in accordance with COS Quality Management System. Equivalence of material and biological properties of human collagen to bovine collagen will also be demonstrated.
• Design of a device for MPC delivery. COS will work with UZH on the development of a syringe device that will mix and deliver MPCs with collagen at point of care.